NCT05950399Completed
Stress Echocardiography to Identify Chemotherapy Induced Cardiotoxicity in Cancer Patients With Heart Failure Risk
Evaluating Changes in Cardiac Function During Stress Echocardiography for the Identification of Chemotherapy Induced Cardiotoxicity in Cancer Patients at Risk of Developing Heart Failure
Source: ClinicalTrials.gov · Last updated 3 Apr 2024
Brief summary (registry, in English)
This clinical trial evaluates changes in cardiac (heart) function during stress echocardiography to screen for chemically induced cardiotoxicity in cancer patients at a high risk for developing heart failure. Some chemotherapeutic agents to treat certain types of cancers can induce cardiac dysfunction and heart failure. Currently there is no validated means of predicting which patients will go on to develop cardiac toxicity and heart failure following treatment with chemotherapeutic agents. Stress echocardiography is a test that uses ultrasound imaging to show how well the heart muscle is working to pump blood to the body during low intensity exercise. Stress echocardiography prior to and during cancer treatment may help doctors find cancer therapeutic related cardiac dysfunction sooner when it may be easier to treat.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 52 (actual)
- First submitted
- 10 Jul 2023
- Start date
- 29 Jun 2015
- Primary completion date
- 19 Mar 2024
- Lead sponsor
- Mayo Clinic
- Diseases
- Heart failure
- NCT number
- NCT05950399
What you commit to
- Study type: Interventional
- Participants enrolled: 52
- From 29 Jun 2015 to the primary completion date, 19 Mar 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Coronary artery disease
- Significant (more than mild) valvular heart disease
- Pre-existing heart failure
- Severe pulmonary disease limiting ability to perform low intensity exercise on a stationary bicycle
Other
- Pre-existing cardiomyopathy
- Musculoskeletal or neurologic abnormality prohibiting low intensity exercise on a stationary bicycle
Who the study is looking for
- Current or previous diagnosis of solid organ cancers (breast, non-small cell lung, rectal, renal, hepatic cancer, metastatic melanoma, sarcoma) or hematological disease (lymphoma, leukemia, multiple myeloma, monoclonal gammopathy of undetermined significance \[MGUS\])
- Age \>= 18 years at study enrollment
- Plan to receive, or history of having received, chemotherapy (anthracycline, alkylating agent \[cyclophosphamide, ifosfamide\], and/or antimicrotubule agent \[docetaxel, paclitaxel\]) with or without specific targeted therapies;
- Anti-HER2 targeted therapies (trastuzumab, pertuzumab)
- Vascular endothelial growth factor (VEGF) inhibitors (bevacizumab, sunitinib, sorafenib, pazopanib, axitinib, vandetanib)
- Immune checkpoint inhibitors (ipilimumab, nivolumab, pembrolizumab)
- Plan to undergo conditioning chemotherapy for bone marrow transplantation (autologous/allogeneic)
Age in the registry: 18 years to - · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic in Rochester Coordinator of this site? Confirm its status | Rochester | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.